Below you will find currently recruiting clinical trials for cancer patients — one click lets you show only trials conducted in Poland. The list is automatically updated from the ClinicalTrials.gov database, and we translate descriptions into Polish.
This is not medical advice — consult your oncologist
Descriptions are automatically translated with AI assistance. Always verify details in the original on ClinicalTrials.gov and consult your treating physician.
Znaleziono 6 z 1410 badań
The aim of this study is to evaluate the efficacy of nab-paclitaxel (on days 1 and 8 of a 21-day cycle) compared to the standard regimen of docetaxel plus carboplatin, both combined with trastuzumab and pertuzumab, as neoadjuvant therapies for HER2-positive breast cancer.
This prospective, response-guided phase II study investigates individualized neoadjuvant treatment strategies for patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. After receiving neoadjuvant dual-HER2-targeted therapy with chemotherapy, patients are evaluated for their treatment response. Those achieving an adequate response continue the therapy, whereas patients with a suboptimal response transition to an intensified investigational regimen incorporating novel targeted agents. This adaptive approach aims to optimize pathologic response, minimize unnecessary toxicity, and explore more effective treatment options for individuals with insufficient benefit from conventional neoadjuvant therapy.
This study is a prospective, open-label, phase II clinical study for patients with HR+/HER2- advanced breast cancer.
The purpose of this study is to establish a prospective, single-center platform research based on clinical subtypes to explore precision neoadjuvant therapy in patients with operable breast cancer who met the indications for neoadjuvant chemotherapy and by the update of basic translational research in the center, especially the refinement of typing, the discovery of new targets and the development of novel targeted drugs, verified the effectiveness of new targeted drugs in neoadjuvant therapy.
This study is to evaluate the efficacy and safety of QL1706 plus albumin-bound paclitaxel ± bevacizumab in 1L treatment of r/mTNBC
Badanie sprawdza skuteczność i bezpieczeństwo leczenia połączeniem trzech leków: LM-108, toripalimabu i chemioterapii (nab-paclitaxel lub eribulin) u pacjentek z zaawansowanym rakiem piersi triple-negative, który powrócił lub rozprzestrzeniał się na inne części ciała.
It is a study of a new therapy or drug involving patients, conducted according to a strict protocol and under medical supervision. For many cancer patients, it provides access to therapies that are not yet standardly available.
Participation is free for the patient — the costs of the tested treatment are covered by the trial sponsor. Some trials also reimburse travel and accommodation costs.
Start with the trial card in our Radar — you will find eligibility criteria and contact details of the center from ClinicalTrials.gov there. Contact is usually in English; if you need support, write to us.
radar.footerNote
Alerts for new trials →